DARUNAVIR ACCORD 400mg tablets medication leaflet

J05AE10 darunavir • Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors

Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for viral replication, thereby reducing the viral load.

The medication is taken orally, usually once daily, in combination with other antiretroviral drugs. Common side effects include nausea, diarrhea, headaches, and skin rashes.

Darunavir is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe hepatic conditions.

This medication is an important option for managing HIV infection, helping to improve patients' quality of life and prevent disease progression.

General data about DARUNAVIR ACCORD 400mg

Substance: darunavir

Date of last drug list: 01-01-2021

Commercial code: W67235001

Concentration: 400mg

Pharmaceutical form: tablets

Quantity: 480

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: LABORATORI FUNDACIÓ DAU - SPANIA

Holder: ACCORD HEALTHCARE POLSKA SP. Z.O.O. - POLONIA

Number: 13010/2020/01

Shelf life: 36 months

Pharmaceutical forms available for darunavir

Concentrations available for darunavir

100mg/ml, 150mg, 300mg, 400mg, 600mg, 75mg, 800mg